Yossef Av-Gay

Source: Wikipedia, the free encyclopedia.
Israeli
EducationTel Aviv University (BSc, MSc, PhD)
Occupation(s)University professor, adjunct professor, researcher, microbiologist
Years active1980–present
Medical career
InstitutionsUniversity of British Columbia, Canada
Ben-Gurion University of the Negev, Israel
ResearchMicrobiology

Yossef Av-Gay (born 1961) is a Canadian

Infectious Diseases in the Faculty of Medicine at the University of British Columbia, Canada.[1] He is also an associate member of the department of microbiology and immunology and holds an adjunct professorship at the medical school of Ben-Gurion University of the Negev
, Israel.

Education

Av-Gay received his BSc in Biology, MSc in Microbiology, and PhD in Microbial Genetics – all from

, Vancouver, Canada.

Research work

He became a microbiologist after education and training. Having been recognized for his research interests, which lies on diseases including chronic

(NTM) diseases. He explores molecular events that govern host-pathogen interactions and the ability of mycobacteria to block the immune response to infection.

Av-Gay's research is geared towards the identification and characterization of novel drugs and drug targets in Mycobacterium tuberculosis,[2] and COVID-19.[3]

His early works were characterized and identified

macrophages
.

Av-Gay's most significant discovery was the identification and characterization of PtpA, a protein phosphatase in Mtb which inhibits the normal macrophage response to infection.[4]

Av-Gay authored over 100 peer review scientific publications, review articles, book chapters and 15 patents; he served as an editor for the

NASDAQ
traded company Beyond Air.

References

  1. ^ "Yossef Av-Gay | Infectious Diseases". UBC Canada.
  2. ^ "ATS: High-dose nitric oxide looks promising for infants with bronchiolitis". MDedge.
  3. PMID 36508083
    .
  4. .
  5. .

External links